NASDAQ:CRISCuris Stock Price, Forecast & News

Curis' stock was trading at $1.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRIS shares have increased by 8.3% and is now trading at $1.18. View which stocks have been most impacted by Coronavirus.

Curis is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Curis.

Curis, Inc. (NASDAQ:CRIS) issued its earnings results on Tuesday, May, 12th. The biotechnology company reported ($0.28) EPS for the quarter. The biotechnology company had revenue of $2.71 million for the quarter. During the same period in the previous year, the firm earned ($0.33) earnings per share. View Curis' earnings history.

Curis's stock reverse split on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 29th 2018. An investor that had 100 shares of Curis stock prior to the reverse split would have 20 shares after the split.

News coverage about CRIS stock has trended negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Curis earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the near term. View the latest news about Curis.

Curis saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 42,600 shares, a decline of 41.1% from the May 31st total of 72,300 shares. Based on an average trading volume of 247,700 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the company's shares are sold short. View Curis' Current Options Chain.

Some companies that are related to Curis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Novavax (NVAX), Celldex Therapeutics (CLDX), Micron Technology (MU), Crispr Therapeutics (CRSP), CTI BioPharma (CTIC), Inovio Pharmaceuticals (INO), Zynga (ZNGA), Agenus (AGEN) and Geron (GERN).

Curis trades on the NASDAQ under the ticker symbol "CRIS."

Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CRIS stock can currently be purchased for approximately $1.18.

Curis has a market capitalization of $43.16 million and generates $10 million in revenue each year. Curis employs 55 workers across the globe.

The official website for Curis is www.curis.com.

Curis' mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected]